Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INGN 225 Vaccine with or without ATRA in Extensive Stage SCLC
NCT00617409Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2007
- Primary completion
- Sep 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Ad.p53-DC vaccine in small cell lung cancer (SCLC), sponsored by Moffitt Cancer Center. Started Oct 2007; status: completed.
02
Drugs
Ad.p53-DC vaccine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00617409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617409.